Valitor's VLTR-559 shows strong 6-month durability for wet AMD treatment in preclinical tests.

Valitor announced preclinical data for VLTR-559, a long-acting anti-VEGF biologic designed to treat wet age-related macular degeneration (AMD) with twice-yearly dosing. The data showed VLTR-559 has a longer vitreous half-life of 12 days compared to 3-5 days for current treatments, maintaining potency and safety over 76 days in ocular tissues. This suggests VLTR-559 could reduce treatment frequency and burden for patients. Valitor plans to advance VLTR-559 into clinical trials next year, aiming to transform wet AMD treatment with a reliable 6-month dosing protocol.